Loading…

Preliminary Studies on Antigenic Variation of Poliovirus Using Neutralizing Monoclonal Antibodies

Institute of Medical Biology, Chinese Academy of Medical Sciences, Kunming, China Cross-neutralization assays were done using 85 strains of poliovirus type 1 with five groups of monoclonal antibodies. These strains were classified into 10 subgroups which had marked differences in antigenicity. Subgr...

Full description

Saved in:
Bibliographic Details
Published in:Journal of general virology 1987-04, Vol.68 (4), p.989-994
Main Authors: Ren, Guo, En-Hua, Tang, Hong, Wang, Xiao-Feng, Yang, Ming-Ying, Liu, Hong-Xing, Qin, Qi-Han, Li, Jun-Ying, Zhuang, Kai-Ming, Liu
Format: Article
Language:English
Subjects:
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Institute of Medical Biology, Chinese Academy of Medical Sciences, Kunming, China Cross-neutralization assays were done using 85 strains of poliovirus type 1 with five groups of monoclonal antibodies. These strains were classified into 10 subgroups which had marked differences in antigenicity. Subgroups P1-2 (28%) and P1-5 (43%) were dominant and have been epidemic in China in recent years. These two subgroups were antigenically different from the Sabin-1 strain, but according to their responses to one group of monoclonal antibodies they had antigenic epitopes in common with the Mahoney and Brunhilde strains. Similarly, 91 strains of type 3 poliovirus were classified into six subgroups with another five groups of monoclonal antibodies. The results showed that strain P3/Yunnan/2/84, which was isolated from cases of poliomyelitis in a local epidemic in the Yunnan province of China in 1984, and strain P3/Finland/23127/84, which was isolated in Finland in 1984, were both antigenically different from the Sabin-3 strain and the reference virulent strain. Keywords: poliovirus, antigenic variation, monoclonal antibodies Received 14 August 1986; accepted 14 January 1987.
ISSN:0022-1317
1465-2099
DOI:10.1099/0022-1317-68-4-989